Adoptive transfer of wild-type CD8+ T cells partially improves disease outcome in Theiler’s murine encephalomyelitis virus-infected OT-I mice
Theiler’s murine encephalomyelitis virus (TMEV) represents a well-established experimental model for the progressive form of multiple sclerosis in susceptible SJL mice. In contrast, resistant C57BL/6 mice are able to completely clear the virus. Our previous data showed that OT-I mice on a resistant C57BL/6-background, which express an MHC-I-restricted T cell receptor specific for the chicken ovalbumin, are rendered susceptible to experimental intracerebral infection with TMEV. They also showed viral spread into the spinal cord due to an impaired T cell response. Because CD8 + T cells substantially contribute to anti-viral adaptive immune responses, we investigated whether an adoptive transfer of CD8 + T cells with a fully functional T cell receptor repertoire may modify the disease course of TMEV in OT-I mice regarding clinical progression and pathological manifestation. We assessed clinical progression and histomorphologic changes, evaluated T cell activation and migration by flow cytometry, and performed neurofilament light chain serum analysis. Viral load was quantified by immunohistochemistry and gene expression by RNA sequencing. Transfer of 5 × 10 6 CD8 + T cells into TMEV-infected OT-I mice attenuated clinical progression, significantly increased survival, and reduced clinical score, viral load, and inflammatory score. Flow cytometry revealed that transferred red fluorescent protein -CD8 + T cells constituted the majority of activated/effectorCD8 + T cells in the brain, and RNA sequencing confirmed the enhancement of an ongoing adaptive immune response. However, a complete rescue and long-term survival of TMEV-infected OT-I mice could not be achieved.
Authors
- Alexander Flügel (ORCID: https://orcid.org/0000-0001-5387-1860)
- Rouven Wannemacher (ORCID: https://orcid.org/0000-0002-7901-7141)
- Felix Stegmann
- Fred Lühder (ORCID: https://orcid.org/0000-0001-6103-9425)
- Bernd Lepenies (ORCID: https://orcid.org/0000-0001-9033-5522)
- Klaus Schughart (ORCID: https://orcid.org/0000-0002-6824-7523)
- Wolfgang Baumgärtner (ORCID: https://orcid.org/0000-0001-8151-5644)
- Kirsten Hülskötter (ORCID: https://orcid.org/0000-0003-1577-5856)
- Virginie Sippel (ORCID: https://orcid.org/0000-0002-2547-3758)
- Robert Geffers (ORCID: https://orcid.org/0000-0003-4409-016X)
- Michel Alexander Steiner (ORCID: https://orcid.org/0000-0001-9923-6555)
- Karl Röhn
- Anna Segna
- Mara Lombardo
- Charlotte Kinder
Institutions
- University of Tennessee Health Science Center (US)
- University of Veterinary Medicine Hannover, Foundation (DE)
- University of Münster (DE)
- Universitätsmedizin Göttingen (DE)
- Helmholtz Centre for Infection Research (DE)
- Hannover Re (Germany) (DE)
- Idorsia Pharmaceuticals Ltd (Switzerland) (CH)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-11-19
- DOI
- https://doi.org/10.3389/fimmu.2026.1963521
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00